

Control for NR-3094 (antiserum, Rabbit)

Catalog No. NR-3095

This reagent is the property of the U.S. Government.

Lot (NIAID Catalog) No. G033-501-565

For research use only. Not for human use.

Contributor:

National Institutes of Allergy and Infectious Diseases (NIAID),
National Institutes of Health (NIH)

Product Description:

Reagent: Control antiserum for NR-3094

Host: Rabbit

Immunizing Antigen: Culture supernatant fluids of unstimulated mouse spleen cells, partially purified by control pore glass bead absorption and gel filtration

NIAID Class: Research Reference Reagent

Research Reference Reagent Note (attached): No. 33

Adjuvant used: Freund's complete plus 30 % Arlacel A

Material Provided/Storage:

Composition: Lyophilized

Original Volume: 1.0 mL

Storage Temperature: 4°C or colder

Reconstitution: 1.0 mL sterile distilled water

Functional Activity:

Neutralizing Titer: No neutralizing activity against murine interferon gamma was observed

Producer and Contract:

University of Texas Medical Branch, Galveston N01-AI-02659

Citation:

Acknowledgment for publications should read "The following reagent was obtained through the NIH Biodefense and Emerging Infections Research Resources Repository, NIAID, NIH: Control for NR-3094 (antiserum, Rabbit), NR-3095."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. Biosafety in Microbiological and Biomedical Laboratories. 5th ed. Washington, DC: U.S. Government Printing Office, 2007; see www.cdc.gov/od/ohs/biosfty/bmbl5/bmbl5toc.htm.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at www.beiresources.org.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC® nor the U.S. Government make any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC® nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC® and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC®, their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

1. Georgiades, J. A., M. P. Langford, G. J. Stanton, and H. M. Johnson. "Purification and Potentiation of Human Immune Interferon Activity." IRCS Medical Science 7 (1979): 559.
2. Langford, M. P., et al. "Large-Scale Production and Physicochemical Characterization of Human Immune Interferon." Infect. Immun. 26 (1979): 36-41. PubMed: 40881.
3. Osborne, L. C., J. A. Georgiades, and H. M. Johnson. "Classification of Interferons with Antibody to Immune Interferon." Cell. Immunol. 53 (1980): 65-70. PubMed: 6157486.

ATCC® is a trademark of the American Type Culture Collection.



RESEARCH REFERENCE REAGENT NOTE No. 33

Control Antiserum to Mouse Gamma Interferon

Catalog Number G033-501-565

RESEARCH RESOURCES SECTION
National Institute of Allergy and Infectious Diseases
National Institutes of Health
Bethesda, Maryland 20205
August 1984

Preparation

Mock* gamma interferon (IFN γ) was prepared from culture supernatants of unstimulated mouse spleen cells and partially purified by a two-step procedure: control pore glass (CPG) bead absorption and elution with phosphate-buffered saline (PBS), pH 7.2, and 1.0 M NaCl followed by Ultrogel AcA 54 column purification (gel filtration) as previously described (1,2). Mock IFN γ preparations were emulsified with an equal volume of Freund's complete adjuvant and 30% Arlacel A and injected intramuscularly and/or subcutaneously on days 1, 4, 14 and 43. Then mock IFN γ preparations were mixed with Freund's incomplete adjuvant and injected intramuscularly or subcutaneously at monthly intervals as previously described for production of antibody to human IFN γ (3).

For preparation of mock antiglobulin to mouse IFN γ , sera were pooled. The globulin (50% ammonium sulfate precipitate) fraction of the pooled sera was harvested and extensively dialyzed against PBS. The mock anti-globulin to human IFN γ was absorbed with 10^7 mouse spleen cells and 10^7 mouse L cells for each ml of mock antiserum by incubation for 1 hr at 37°C. The mock antiserum (560 ml) was then absorbed twice with 25 ml of Sepharose beads that had fetal calf serum, mock IFN γ , and mouse spleen cell sonicate proteins bound to it by the cyanogen bromide activation method. These absorption procedures eliminated gross contamination of antibodies to serum and cell proteins as detected by Ouchterlony immunoprecipitation on microscope slides. The pooled mock anti-globulins to mouse IFN γ were aliquoted into vaccine vials (1.0 ml), frozen, lyophilized to dryness and vacuum sealed.

Recommendations for Reconstitution

Add 1.0 ml of sterile distilled water or an appropriate medium to the lyophilized powder. The reconstituted globulin can be stored indefinitely at -20°C or lower.

*The initial agreement was to provide the reagents in two phases, half after the first year, and the balance after the second year. This was changed at the request of NIH at the end of the first year and the reagents were provided in one lot at the end of the second year. The constraints of the altered agreement resulted in insufficient mock antibodies produced as described above. Mock antibodies that were provided to NIH were thus processed normal rabbit sera that were compared to the above mock antibody preparations for neutralizing activity against IFN γ in both the mouse and human systems.

Interferon Neutralization Assay

Half-log dilutions of test sera are mixed with equal volumes (0.2 ml) of IFN γ . The final concentration of IFN γ is approximately 10 units/ml. A unit of mouse IFN γ is defined as the concentration of IFN required to reduce vesicular stomatitis virus (40-60 pfu/well) plaques by 50% on mouse L cells in microtiter plates. After 1 hr incubation at room temperature, the individual mixtures of antisera and IFN are added to target cells in triplicate (0.1 ml/well). Residual IFN titers are determined and the dilution of antiserum required to reduce 10 units IFN γ /ml to 1 unit is calculated. One unit of antiserum is the concentration expressed in 1 ml volume that will neutralize 10 units of IFN γ .

Potency

No neutralizing activity of mouse IFN γ was observed with the control antiserum.

Results of Other Tests

The control antiserum did not neutralize: the natural killing (NK) cell enhancing activity of mouse IFN γ , the antiviral activity of mouse recombinant IFN γ , and interleukin 2 enhancement of NK activity.

Use of Reference Antiserum

The purpose of this antiserum is to provide a reference reagent which can be used in conjunction with antiserum to mouse IFN γ for the identification and characterization of biological and chemical properties attributed to mouse interferon. The wide use of interferon in research has made it desirable to have standards which may be used to correlate data from different laboratories. This reagent is available in limited quantities and should be used only after preliminary studies have been performed.

The source of the reagent should be identified in each publication and a copy of all publications should be sent to the NIAID Antiviral Substances Program, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20205.

Stability

Freeze-dried serum globulins are generally stable at room temperature (23°C) for indeterminate lengths of time. It is recommended, however, that the unopened ampules be stored at +4°C or lower temperatures. The reconstituted globulin should be stored at -20°C or lower.

Prepared by: Howard M. Johnson, G. John Stanton, and
Marlyn P. Langford
Department of Microbiology
The University of Texas Medical Branch
Galveston, Texas 77550
Contract No. AI 02659

References

1. Georgiades, J.A., Langford, M.P., Stanton, G.J., and Johnson, H.M. (1979) IRCS Medical Science 7:559.
2. Langford, M.P., Georgiades, J.A., Dianzani, F., Stanton, G.J., and Johnson, H.M. (1979) Infect. Immun. 26:36-41.
3. Osborne, L.C., Georgiades, J.A., and Johnson, H.M. (1980) Cell. Immunol. 53:65-70.